Clinical Trial Update: A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on Nuzefatide Pevedotin (BT5528) for metastatic pancreatic ductal adenocarcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Nuzefatide Pevedotin (BT5528)

Snippet

Sponsor: BicycleTx Limited | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Status: RECRUITING